# Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer

> **NCT04337580** · PHASE2 · RECRUITING · sponsor: **Wake Forest University Health Sciences** · enrollment: 50 (estimated)

## Conditions studied

- Prostate Cancer
- Refractory Cancer
- Castration Resistant Prostatic Cancer

## Interventions

- **DRUG:** Omeprazole 80 mg twice daily

## Key facts

- **NCT ID:** NCT04337580
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-03-05
- **Primary completion:** 2028-02
- **Final completion:** 2028-03
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04337580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04337580, "Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04337580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*